STOCK TITAN

Teknova Introduces Proprietary Express-Tek℠ Production Service and Expanded Manufacturing Grade Options to Expedite Novel Therapy Development

Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Neutral)
Tags

Teknova (NASDAQ: TKNO) has launched two new offerings to enhance product customization and expedite novel therapy development:

  • Express-Tek℠ Production: A proprietary service that reduces custom product turnaround time by an average of two weeks, allowing products to enter production in days instead of weeks.
  • RUO+ Manufacturing Grade: A new grade bridging the gap between research and clinical-grade production, providing a seamless and cost-effective option for scaling from discovery to clinical manufacturing.

These offerings aim to accelerate therapeutic development by providing faster manufacturing, delivery of critical reagents, and flexible scaling options for customers transitioning from research to clinical trials.

Loading...
Loading translation...

Positive

  • Introduction of Express-Tek℠ Production service, reducing custom product turnaround time by an average of two weeks
  • Launch of RUO+ manufacturing grade, providing a cost-effective option for scaling from research to clinical production
  • Expansion of product customization options, potentially attracting more customers and increasing market share

Negative

  • None.

News Market Reaction

-2.22%
1 alert
-2.22% News Effect

On the day this news was published, TKNO declined 2.22%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Express-TekSM Production enables customers to have their products enter production in days instead of weeks, significantly shortening turnaround time

New manufacturing grade, RUO+, provides a seamless and cost-effective option for customers as they transition from RUO to GMP

HOLLISTER, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today launched two new offerings to provide customers with increased product customization options: Express-TekSM Production, to expedite the manufacturing and delivery of critical customer reagents, and a new manufacturing grade, RUO+, that enables customers to scale efficiently from discovery through process development and into clinical manufacturing.

“Our focus is to make solutions possible for our customers, and our thoughtful team continues to find innovative and impactful ways to help make therapeutic development easier and faster,” said Stephen Gunstream, President and Chief Executive Officer. “With the launch of our most recent offerings, we’re providing even more ways for our customers to customize and tailor their reagent manufacturing and accelerate the introduction of novel therapies. Express-Tek Production enables custom products to enter production in days instead of weeks. Teknova is already a leader in turnaround time for custom reagents, and we know how important it is for our customers to get critical products as quickly as possible. And, with Express-Tek, customers have our guarantee – if we don’t hit our date, then we’ll cover the expediting fee.”

Express-Tek Production is an expedited, proprietary service offering for customers with compressed timelines that reduces overall turnaround time of custom products by an average of two weeks, without compromising quality. By opting to pre-order raw materials, select prioritized manufacturing to secure the next spot in line for production, or choose expedited shipping options, Express-Tek Production helps customers get the products they need as soon as possible, guaranteed.

“We’re also introducing a new manufacturing grade to provide our customers with additional flexibility as they scale from research through commercialization,” continued Mr. Gunstream. “This new grade, called ‘RUO+’, is unique to Teknova and combines research-grade flexibility with clinical-grade production. We’ve heard from our customers that not having the right manufacturing grade at the right time can slow down their development by complicating process or technology transfer. The availability of RUO+ will allow them to scale seamlessly as they work towards a clinical trial.”

Teknova’s new manufacturing grade, RUO+, is an efficient and cost-effective solution that bridges the gap between research- and clinical-grade production. With RUO+, custom reagents are manufactured using the same validated facilities, equipment, and processes as GMP-grade products, providing comparable quality without the added documentation and testing requirements that GMP demands. The addition of RUO+, alongside Teknova’s pre-existing research- and GMP-grade options, equips novel therapy developers with a complete range of manufacturing grades for wherever they are in the clinical development pipeline.

Both Express-Tek Production and RUO+ are available starting today. Customers can select and include either offering as part of the custom reagent order process, which can be initiated by phone, email, or by using Teknova’s online custom order form.

For more information about Express-Tek Production, click here.

For more information about Teknova’s manufacturing grades, including RUO+, click here.

ABOUT TEKNOVA
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.

Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100

Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259


FAQ

What is Teknova's new Express-Tek℠ Production service for TKNO stock investors?

Express-Tek℠ Production is Teknova's new proprietary service that expedites manufacturing and delivery of custom reagents, reducing turnaround time by an average of two weeks. This service allows products to enter production in days instead of weeks, potentially improving Teknova's competitive position and revenue generation.

How does Teknova's new RUO+ manufacturing grade benefit TKNO shareholders?

The RUO+ manufacturing grade provides a cost-effective option for Teknova's customers to scale from research to clinical production. This new offering bridges the gap between research and GMP-grade production, potentially attracting more customers and increasing Teknova's market share in the biotechnology reagents sector.

When will Teknova's Express-Tek℠ Production and RUO+ services be available for TKNO customers?

Both Express-Tek℠ Production and RUO+ manufacturing grade services are available starting August 13, 2024. Customers can select and include either offering as part of the custom reagent order process through phone, email, or Teknova's online custom order form.

How might Teknova's new offerings impact TKNO stock performance?

The introduction of Express-Tek℠ Production and RUO+ manufacturing grade could potentially boost TKNO stock performance by attracting more customers, increasing market share, and improving revenue generation through faster turnaround times and more flexible manufacturing options for clients in the biotechnology sector.
Alpha Teknova

NASDAQ:TKNO

TKNO Rankings

TKNO Latest News

TKNO Latest SEC Filings

TKNO Stock Data

220.54M
10.08M
10.82%
85.26%
4.99%
Drug Manufacturers - Specialty & Generic
In Vitro & in Vivo Diagnostic Substances
Link
United States
HOLLISTER